Authorized by 42 U.S.C. 282(b)(16), section 402(b)(16) of the Public Health Services (PHS) Act, as amended. The National
Institutes of Health (NIH) Clinical Center Research Hospital Board (Board) is governed by the provisions of the Federal Advisory
Committee Act, as amended (5 U.S.C. §§ 1001-1014).
Objectives and Scope of Activities
The purpose of the Board is to advise, consult with, and make recommendations to the NIH Director (or designee) and the NIH
Clinical Center Chief Executive Officer (CEO) with respect to maintaining excellence in hospital operations, safety and quality,
unique clinical research care requirements for Clinical Center patients, regulatory compliance, clinical research, and hospital
leadership performance oversight. The Board's advice and recommendations may regard issues, processes, studies, and/or reports
on a range of topics in relation to the NIH Clinical Center and CEO's duties and authorities.
Description of Duties
The purpose of the Board is to provide advice and recommendations to the NIH Director (or designee) and CEO of the NIH Clinical
Center on the NIH Clinical Center's policies and procedures regarding hospital operations, safety and quality, and regulatory
compliance. Using leading institutions in health care and research as benchmarks, the Board will provide advice in the following
areas:
Management, quality and safety, and compliance of hospital operations
Policies and organizational approaches that promote quality and safety
Risk areas that need to be addressed by hospital and agency leadership
Implementation of policies and strategic plans
Requirements for hospital leadership
Performance of the CEO including evaluation based on operating plans and quality metrics
The Board may request reports on quality and safety measures, risk assessment, violations and remediation measures/corrective
action plans, and additional measures.
The duties of the Board are solely advisory and shall extend only to the submission of advice and recommendations to the NIH
Director (or designee) and CEO of the NIH Clinical Center, which will be non-binding to the NIH. No determination of fact or
policy will be made by the Board. Unlike hospital boards in the community, the Board does not have financial authority.
Agency or Official to Whom the Committee Reports
The Board will advise, consult with, and make recommendations to the NIH Director (or designee) and CEO of the NIH Clinical
Center.
Support
Management and support services will be provided by the Office of the Director, NIH in collaboration with the Office of the
Chief Executive Officer, NIH Clinical Center.
Estimated Annual Operating Costs and Staff Years
Estimated annual cost for operating the Board, including compensation and travel expenses for members, but excluding staff
support, is $173,644. The estimate of annual person-years of staff support required is 0.1, at an estimated annual cost of
$9,410.
Designated Federal Official
The NIH Director will assign a full-time or permanent part-time employee as the Designated Federal Officer (DFO) of the Board.
In the event that the DFO cannot fulfill the assigned duties of the Committee, one or more full-time or permanent part-time NIH
employees will be assigned as DFO and carry out these duties on a temporary basis.
The DFO will approve all of the Board’s and subcommittees’ meetings, prepare and approve all meeting agendas, attend all Board
and subcommittee meetings, adjourn any meeting when it is determined to be in the public interest, and chair meetings when
directed to do so by the official to whom the committee reports.
Estimated Number and Frequency of Meetings
The Board will meet approximately three times within a fiscal year. Meetings will be open to the public except as determined by
the Secretary of Health and Human Services (Secretary) at the request of the DFO in accordance with 5 U.S.C. 552b(c) and 41
C.F.R. 102-3.155 including specifying the specific exception(s) that justifies closure. Notice of all meetings will be given to
the public. In the event a portion of a meeting is closed to the public, as determined by the Secretary in accordance with the
Government in the Sunshine Act (5 U.S.C. 552b(c)) and the Federal Advisory Committee Act, an annual report of closed or
partially-closed meetings will be prepared which will contain, at a minimum, a list of members and their business addresses, the
Committee’s functions, dates and places of meetings, and a summary of the Committee’s activities and recommendations made during
the fiscal year.
Duration
Continuing.
Termination
Unless renewed by appropriate action, the NIH Clinical Center Research Hospital Board will terminate two years from the date the
charter is filed.
Membership and Designation
The Board will consist of up to 14 non-federal members, including the chair, appointed by the NIH Director. The appointed
members will consist of (a) authorities who are nationally recognized leaders in sectors related to the NIH Clinical Center’s
duties and authorities, including but not limited to research hospital administration/operations, clinical care, safety and
quality, clinical and research compliance, or clinical research, and (b) two individuals who have participated in clinical
research studies as patients. Appointed members will be selected from the academic and private sector research community, as
well as the general public.
Appointed members must be eligible to serve as Special Government Employees (SGEs) and will serve as SGEs, as defined by 18
U.S.C. § 202. Members and the chair will be invited to serve for overlapping terms of up to four years. Terms of more than two
years are contingent upon the renewal of the Board charter by appropriate action prior to its termination. Members may serve
after the expiration of their terms until their successors have taken office. A quorum for the conduct of business by the full
committee will consist of a majority of currently appointed members.
Subcommittees
As necessary, subcommittees and ad hoc working groups may be established by the DFO within the Board’s jurisdiction. The
advice/recommendations of a subcommittee/working group must be deliberated by the parent advisory committee, which is the Board.
A subcommittee/working group may not report directly to a Federal official unless there is statutory authority to do so.
Subcommittee membership may be drawn in whole or in part from the parent advisory committee. All subcommittee members may vote
on subcommittee actions and all subcommittee members count towards the quorum for a subcommittee meeting. Ad hoc consultants are
not members, do not count towards the quorum, and may not vote. A quorum for a subcommittee will be three members. The
Department Committee Management Officer will be notified upon establishment of each standing subcommittee and will be provided
information on its name, membership, function, and estimated frequency of meetings.
Recordkeeping
Meetings of the committee and its subcommittees will be conducted according to the Federal Advisory Committee Act, other
applicable laws and Departmental policies. Committee and subcommittee records will be handled in accordance with General Records
Schedule 6.2, Federal Advisory Committee Records, or other approved agency records disposition schedule. These records will be
available for public inspection and copying, subject to any applicable exemptions under the Freedom of Information Act, 5 U.S.C.
552(b) and 41 C.F.R. 102-3.170.
